Please login to the form below

Not currently logged in
Email:
Password:

AZ's phase III RA trial underway

AstraZeneca has announced the beginning of phase III clinical trial development for rheumatoid arthritis treatment fostamatinib

AstraZeneca (AZ) has announced the beginning of phase III clinical trial development for rheumatoid arthritis (RA) treatment fostamatinib.

The trial will study the effects of fostamatinib – developed as an oral syk inhibitor – in patients with previously inadequate response to disease-modifying anti-rheumatic drugs (DMARDs).

Syk is a form of tyrosine kinase protein that can lead to the inflammatory conditions of RA when functioning abnormally. Fostamatinib is designed to block the function of syk, halting progression of the disease.

Phase III development of the drug will see three trials assessing its efficacy and safety, including two 12-month studies examining the effect of fostamatinib on patients responding inadequately to DMARDs.

As published in the New England Journal of Medicine, a previous phase II programme demonstrated positive results for the drug, then known as R788, in RA patients who failed to respond adequately to current treatments.

Commenting on the development of fostamatinib, Anders Ekblom, AZ's executive vice president of global medicines development, said: "Patients with rheumatoid arthritis currently have limited treatment options after they stop responding adequately to DMARDs or anti-TNF therapy, and we are hopeful that fostamatinib may represent a novel alternative for patients to help manage their condition beyond this stage."

Fostamatinib was initially developed by Rigel Pharmaceuticals, with AZ purchasing rights to further develop and commercialise the drug in February 2010.

29th September 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics